CN100384475C - Preparation method of magnetic guiding anticancer medicine - Google Patents
Preparation method of magnetic guiding anticancer medicine Download PDFInfo
- Publication number
- CN100384475C CN100384475C CNB021356610A CN02135661A CN100384475C CN 100384475 C CN100384475 C CN 100384475C CN B021356610 A CNB021356610 A CN B021356610A CN 02135661 A CN02135661 A CN 02135661A CN 100384475 C CN100384475 C CN 100384475C
- Authority
- CN
- China
- Prior art keywords
- medicine
- mixture
- magnetic
- arc
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The present invention relates to a preparation method for a magnetic guiding anticancer medicine, which belongs to the field of medical science and particularly to a preparation method of a magnetic medicine on oncology. The method has the technical scheme that a medium containing substitute plasma and an anticancer formulate is added with a magnetic iron carbon adherent agent; thereby, the treating effect is increased, the side effect of an application formulate is reduced, and the use convenience is increased. A conduit tube is led into by approaching to the artery, such as femoral artery under the monitoring of angiography and is led to the feeding artery of tumors. The medicine is used conveniently and does not need preparing before being used, and the medicine is directionally conveyed in surrounding lymph nodes of the tumors, so the medicine can form thrombus in surrounding blood vessels of the tumors, and a medicine treatment concentration area is established to reduce the distribution of poisonous substances in a machine body.
Description
Technical field
The invention belongs to medical domain, particularly the oncology goes up magnetic control medicaments preparation method.
Background technology
Magnetic control is carried anti-tumor agent treatment tumor treatment method, can protect heart, liver, bone marrow and other vital tissue and come to harm.The modern known method that has some to finish magnetic guiding anticancer medicine.What all these methods were used all is that medicine and ferromagnetic particle are combined.These magnetic carriers all have following shortcoming: very big particle or capsule size, and very low magnetic, is difficult in tumor area and forms the medicine collection and deposit less adsorbance, and ingredients is difficult to preparation and preserves and use.What the method that proposes with us was the most approaching is the NO.1722256 Russian Patent, number of patent application is SU4767768, on November 2 1989 applying date, what use as the magnetic carrier of bioactive substance in this patent is the ferrum carbon particle, and this ferrum carbon particle prepares with the thermocatalytic method.These particles only have little adsorbance, and the preparation process complexity of ingredients can not obtain the material of essential attributes and dispersion, and the ingredients emulsion usually will be with directly preparation before use of ultrasonic dispersion.
In the NO.5593740 United States Patent (USP) on January 14th, 1997, describe the preparation equipment and the technology of high dispersion metal powder, comprised the iron powder that is covered with carbon.It is to evaporate in the arcuation plasma jet with metal, then forms graininess in arc chamber outlet cooling, to this zone for Hydrocarbon, propane for example, pyrolysis takes place in it on red-hot surface of metal particles, form carbon film closely.Such particle only has very little absorbability, and is made dirty by thermal decomposition product, is not suitable for medically using.
The objective of the invention is to improve the drug use convenience and need not to prepare before use.Guide cancer therapy drug with magnetic, thereby make it concentrate on the local curative effect that improves of tumor area.Realize that the directed medicine of carrying in tumor lymph node on every side, makes it form thrombosis in the blood vessel around the tumor, set up Drug therapy concentration district to reduce the distribution of toxic medicament in body.
Summary of the invention
The present invention is achieved in that 1, fabrication and processing ferrum carbon dust adsorbent at first, activated carbon (10-1000 μ m) and iron particle (10-100 μ m) pulverized together obtained particles mixture; Ferrum carbon particle mixture is carried out condensing again of plasma chemistry, condense in again in the nitrogen plasma stream in the direct-current plasma generator and carry out, use the quick refrigerated separation of room temperature nitrogen subsequently; The reuse air flow makes the magnetic carrier passivation, does not allow its spontaneous combustion of catching fire; 2, under the ultrasound wave effect, make the ferrum carbon dust in distilled water, form suspension, and in suspension, replenish medicament, after mixing through 1-24 hour, make the suspension precipitation, get rid of clear liquid with centrifuge; 3, in ferrum carbon dust and medicament precipitate, add plasma substitute solution, make and contain 0.1%NaCl, 1% gelatin (or 10% poly-glucose solution or 1% albumin solution or serum) in the mixture, carry out supersound process once more, make the suspension quick freezing then, then carry out the sealed packaging of lyophilization and ingredients.
Description of drawings
Fig. 1 illustrates the particle structure that magnetic guides anticancer ingredients.
The 1st, activated carbon particles group, the 2nd, iron particle, the 3rd, gap, the 4th, medicament cover layer.
The specific embodiment
Use the reduced iron powder of 10-100 micron particle and the activated carbon powder of 10-1000 micron as original component.These powder are mixed be incorporated in the ball mill mutually to grinding 4 hours.The weight quota of ferrum is in the scope of 40-70% in the mixture.This share is decided by the loss amount of various compositions in the whizzer of bottom regelation knot operating mode and plasma generator.The weight quota of ferrum is in the scope of 40-50% in the adhesive agent that obtains after condensing again.
Condense (evaporation is condensed subsequently) of mixture realizes in direct-current plasma generator nitrogen plasma medium again.With nitrogen current mixture is infeeded arc-discharge zone.The electric current of electric arc is the 50-200 ampere, and arc voltage is 200 volts.About 6000 ℃ of the temperature of arc discharge.The component of mixture evaporates in electric arc.Steam cools off with the tangential nitrogen current of room temperature after flowing out arc region.Ferrum carbon adsorbent particle relies on the adhesion and the chemical bond of physics to combine closely in conjunction with formation because ferrum condenses into oversubscription on surfaces of carbon particles loose spherically.Particle is carried by nitrogen current, and is cooled to room temperature.To fail size by arc region greater than 1 micron separate particles with whizzer.The adhesive agent particle for preparing is collected with the pipe box filter.
Because super dispersive iron particle is the energy spontaneous combustion, so adhesive agent possible spontaneous combustion when contacting with atmosphere is used in the method for introducing little air in the adhesive agent container and makes the metal surface partial oxidation make its passivation, to prevent spontaneous combustion.
After carrying out this operation, just the adhesive agent packing can be used for preparing the ingredients of magnetic guiding then.
With ultrasonic Treatment (frequency 20-40Hz; 50-100W/cm
2, 10min) 1 part of weight adhesive agent and 40 parts of distilled water mix and prepare the adhesive agent suspension.The amycin distilled water solution is added in the prepared suspension liquid; Mixture was constantly stirred 3 hours, and during this period, every interval 10 minutes was with ultrasonic Treatment 2 minutes again.The suspension sample is carried out centrifugalize, and the observation supernatant (it should be transparent, and redfree--do not contain and show the amount amycin).In the suspension precipitate, add plasma substitute solution, make and contain 0.1%NaCl, 1% gelatin (or 10% poly-glucose solution or 1% albumin solution or serum) in the mixture, and repeat ultrasonic Treatment, after this realize the quick freezing of suspension, then carry out the lyophilization and the sealing of ingredients.
Prepared ingredients quantitatively divides to install in the little phial of standard, is used for injection, is suitable for long preservation, only needs before using to add distilled water in little phial.
Magnetic guides the treatment of anticancer ingredients to realize with following manner:
The tumor feeding pipe network is carried out the research of careful angiography, thus determine necessary ingredients deal (usually with the amycin dosage of magnetic guiding ingredients only reach the solution amycin 1/10th).
Distilled water is injected little phial obtain the ingredients suspension, in the case of necessary, replenish spasmolytic and other necessary ingredients.
Under angiographic monitoring, introduce conduit by tremulous pulse near (for example passing through femoral artery), it is guided to the feeding artery of tumor.Stacking permanent magnetic field (500-3000 oersted) on the tumor perspective plane and in 20 minutes, realizing that via conduit endarterial ingredients imports.Importing magnetic field, back in ingredients kept 30 minutes.Produce the agglomeration of adhesive agent particle under the effect in magnetic field, cohesion causes its magnetic torque to strengthen, and they are pressed onto the blood vessel end by magnetic field and heap, and are directed to the blood vessel lymph node, and this has just blocked the normal blood supply of tumor cell.This process takes place strongly especially in little blood vessel and blood capillary.Around tumor, form an anticancer Drug Storage.Amycin leaves adhesive agent and relies on desorption, and medicine is occupied by serum in the lip-deep position of adhesive agent, and this process will continue 8-15 round the clock.Realize the continued treatment effect of ingredients in this time period to tumor.
The adhesive agent particle that is adsorbed with amycin is directed near the tumor the lymph node by lymph gland, and amycin also just is brought to these zones, and the there has malignant cell most probably, thereby with its elimination, has therefore prevented transfer.
Toxicity research shows that the magnetic adherence agent is low toxicity (LD50-0.7g/kg).
Claims (1)
1. the preparation method of a magnetic guiding anticancer medicine is characterized in that: fabrication and processing ferrum carbon dust adsorbent at first, 10-1000 μ m activated carbon and 10-100 μ m iron particle are pulverized the acquisition particles mixture together, and wherein the weight quota of ferrum is 40-70% in the mixture; Ferrum carbon particle mixture is carried out condensing again of plasma chemistry, condense in again in the nitrogen plasma stream in the direct-current plasma generator and carry out, with nitrogen current mixture is infeeded arc-discharge zone, the electric current of electric arc is the 50-200 ampere, arc voltage is 200 volts, and the temperature of arc discharge is 6000 ℃; Cool off fast with room temperature nitrogen subsequently, will fail size by arc region greater than 1 micron separate particles; The reuse air flow makes the magnetic carrier passivation, does not allow its spontaneous combustion of catching fire; Under the ultrasound wave effect, make the ferrum carbon dust in distilled water, form suspension, and in suspension, replenish medicament, after mixing through 1-24 hour, make the suspension precipitation, get rid of clear liquid with centrifuge; In ferrum carbon dust and medicament precipitate, add plasma substitute solution, make and contain 0.1%NaCl, 1% gelatin in the mixture, carry out supersound process once more, make the suspension quick freezing then, then carry out the sealed packaging of lyophilization and ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021356610A CN100384475C (en) | 2002-10-29 | 2002-10-29 | Preparation method of magnetic guiding anticancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021356610A CN100384475C (en) | 2002-10-29 | 2002-10-29 | Preparation method of magnetic guiding anticancer medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1493360A CN1493360A (en) | 2004-05-05 |
| CN100384475C true CN100384475C (en) | 2008-04-30 |
Family
ID=34231469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021356610A Expired - Fee Related CN100384475C (en) | 2002-10-29 | 2002-10-29 | Preparation method of magnetic guiding anticancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100384475C (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991006322A1 (en) * | 1989-11-02 | 1991-05-16 | Kholodov Leonid E | Magnetocontrollable carrier with physiologically active substance and method for making said carrier |
| US5593740A (en) * | 1995-01-17 | 1997-01-14 | Synmatix Corporation | Method and apparatus for making carbon-encapsulated ultrafine metal particles |
| CN1303752A (en) * | 1999-12-23 | 2001-07-18 | 武汉大学 | Synthesizing method of metal-in-carbon and metal-in-carbon carbide nanometer micropowder |
| CN1334160A (en) * | 2001-08-09 | 2002-02-06 | 广东工业大学 | Graphite arc discharge method for synthesizing carbon-clad nm ferromagnetic metal particles |
| CN1348362A (en) * | 1998-01-06 | 2002-05-08 | 费克斯公司 | Magnetically responsive composition |
-
2002
- 2002-10-29 CN CNB021356610A patent/CN100384475C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991006322A1 (en) * | 1989-11-02 | 1991-05-16 | Kholodov Leonid E | Magnetocontrollable carrier with physiologically active substance and method for making said carrier |
| US5593740A (en) * | 1995-01-17 | 1997-01-14 | Synmatix Corporation | Method and apparatus for making carbon-encapsulated ultrafine metal particles |
| CN1348362A (en) * | 1998-01-06 | 2002-05-08 | 费克斯公司 | Magnetically responsive composition |
| CN1303752A (en) * | 1999-12-23 | 2001-07-18 | 武汉大学 | Synthesizing method of metal-in-carbon and metal-in-carbon carbide nanometer micropowder |
| CN1334160A (en) * | 2001-08-09 | 2002-02-06 | 广东工业大学 | Graphite arc discharge method for synthesizing carbon-clad nm ferromagnetic metal particles |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1493360A (en) | 2004-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5236410A (en) | Tumor treatment method | |
| Fang et al. | Biomimetic anti‐PD‐1 peptide‐loaded 2D FePSe3 nanosheets for efficient photothermal and enhanced immune therapy with multimodal MR/PA/thermal imaging | |
| EP0740581B1 (en) | Yttria particulate material | |
| Kwon et al. | Superparamagnetic gold nanoparticles synthesized on protein particle scaffolds for cancer theragnosis | |
| Xu et al. | Cobalt nanoparticles coated with graphitic shells as localized radio frequency absorbers for cancer therapy | |
| Kozak et al. | Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science | |
| Alsowmely et al. | Non‐surgical treatment of hepatocellular carcinoma | |
| JP2005200426A (en) | Magnetic targeted carrier | |
| US20200246458A1 (en) | Method for treating cancer based on metallofullerene monocrystalline nanoparticles that specifically disrupt tumor blood vessels | |
| EP3363496A1 (en) | Magnetic field oscillating at several frequencies for improving efficacy and/or reducing toxicity of magnetic hyperthermia | |
| JPS6187303A (en) | Biological magnetic liquid | |
| Vedernikova | Magnetic nanoparticles: Advantages of using, methods for preparation, characterization, application in pharmacy | |
| WO2004034876A2 (en) | Magnetically guided particles for radiative therapies | |
| CN100384475C (en) | Preparation method of magnetic guiding anticancer medicine | |
| KR101973830B1 (en) | Radioactive compositions and methods for their therapeutic use | |
| JPS61220663A (en) | Method and apparatus for treating disease containing injury and necrosis of tissue | |
| Song et al. | Applications of magnetite nanoparticles in cancer immunotherapies: present hallmarks and future perspectives | |
| Huang et al. | Magnesium trisilicate coated Fe3O4 nanoparticles as prompt and efficient lactic acid removers potential for exercise-induce fatigue prevention | |
| Ahmed et al. | Marrow storage techniques: a clinical comparison of refrigeration versus cryopreservation | |
| Kuznetsov et al. | Ferro-carbon particles: preparation and clinical applications | |
| CN101347455A (en) | Carbon-encapsulated iron nanoparticles and use thereof as vector of medicament for treating liver cancer | |
| Bretcanu et al. | Glasses for treatment of liver cancer by radioembolization | |
| JPH0920687A (en) | Thawing solution of freeze-dry blood | |
| US20070274907A1 (en) | Magnetically Targetable Mitomycin C Compositions and Methods of Their Use | |
| Brusentsov et al. | Principles of magnetohydrodynamic thermochemotherapy of malignant tumors (A review) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080430 Termination date: 20111029 |